MOHAMMAD HASANAIN

Dr. MOHAMMAD HASANAIN

Sylvester Comprehensive Cancer Center, Miami, Florida, USA
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2015 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
MHMOHAMMAD HASANAIN
MOHAMMAD HASANAIN
ABA Bhattacharjee
A Bhattacharjee
PPP Pandey
P Pandey
RAR Ashraf
R Ashraf
NSN Singh
N Singh
JSJ Sarkar
J Sarkar
α-Solanine is a glycoalkaloid found in species of the nightshade family including potato. It was primarily reported to have toxic effects in humans. However, there is a growing body of literature demonstrating in vitro and in vivo anticancer activity of α-solanine. Most of these studies have shown activation of apoptosis as the underlying mechanism in antitumor activity of α-solanine. In this study, we report α-solanine as a potential inducer of autophagy, which may act synergistically or in parallel with apoptosis to exert its cytotoxic effect. Induction of autophagy was demonstrated by several assays including electron microscopy, immunoblotting of autophagy markers and immunofluorescence for LC3 (microtubule-associated protein 1 (MAP1) light chain-3) puncta. α-Solanine-induced autophagic flux was demonstrated by additionally enhanced – turnover of LC3-II and – accumulation of LC3-specific puncta after co-incubation of cells with either of the autophagolysosome inhibitors – chloroquine and – bafilomycin A1. We also demonstrated α-solanine-induced oxidative damage in regulating autophagy where pre-incubation of cells with reactive oxygen species (ROS) scavenger resulted in suppression of CM-H2DCFDA (5 (and 6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate acetyl ester) fluorescence as well as decrease in LC3-II turnover. α-Solanine treatment caused an increase in the expression of endoplasmic reticulum (ER) stress proteins (BiP, activating transcription factor 6 (ATF6), X-box-binding protein 1, PERK, inositol-requiring transmembrane kinase/endonuclease 1, ATF4 and CCAAT-enhancer-binding protein (C/EBP)-homologous protein) suggesting activation of unfolded protein response pathway. Moreover, we found downregulation of phosphorylated Akt (Thr308 and Ser473), mammalian target of rapamycin (mTOR; Ser2448 and Ser2481) and 4E-BP1 (Thr37/46) by α-solanine implying suppression of the Akt/mTOR pathway. Collectively, our results signify that α-solanine induces autophagy to exert anti-proliferative activity by triggering ER stress and inhibiting Akt/mTOR signaling pathway.

2 February 2023 in Nature Cancer
Verified
Journal Article
Open access
PDF file
SMSimona Migliozzi
Simona Migliozzi
YOYoung Taek Oh
Young Taek Oh
MHMOHAMMAD HASANAIN
MOHAMMAD HASANAIN
LGLuciano Garofano
Luciano Garofano
FDFulvio D’aNgelo
Fulvio D’aNgelo
AIAntonio Iavarone
Antonio Iavarone
Despite producing a panoply of potential cancer-specific targets, the proteogenomic characterization of human tumors has yet to demonstrate value for precision cancer medicine. Integrative multi-omics using a machine-learning network identified master kinases responsible for effecting phenotypic hallmarks of functional glioblastoma subtypes. In subtype-matched patient-derived models, we validated PKCδ and DNA-PK as master kinases of glycolytic/plurimetabolic and proliferative/progenitor subtypes, respectively, and qualified the kinases as potent and actionable glioblastoma subtype-specific therapeutic targets. Glioblastoma subtypes were associated with clinical and radiomics features, orthogonally validated by proteomics, phospho-proteomics, metabolomics, lipidomics and acetylomics analyses, and recapitulated in pediatric glioma, breast and lung squamous cell carcinoma, including subtype specificity of PKCδ and DNA-PK activity. We developed a probabilistic classification tool that performs optimally with RNA from frozen and paraffin-embedded tissues, which can be used to evaluate the association of therapeutic response with glioblastoma subtypes and to inform patient selection in prospective clinical trials.

1 August 2015 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
ASAastha Singh
Aastha Singh
KFKaneez Fatima
Kaneez Fatima
Arjun SinghArjun Singh
Arjun Singh
ABAkansha Behl
Akansha Behl
MMM.J. Mintoo
M.J. Mintoo
ANArvind S. Negi
Arvind S. Negi

1 February 2017 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
BKBalagani Sathish Kumar
Balagani Sathish Kumar
KRKusumoori Ravi
Kusumoori Ravi
AVAmit Kumar Verma
Amit Kumar Verma
KFKaneez Fatima
Kaneez Fatima
MHMOHAMMAD HASANAIN
MOHAMMAD HASANAIN
ANArvind S. Negi
Arvind S. Negi

1 May 2018 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
SKSadiya Khwaja
Sadiya Khwaja
KFKaneez Fatima
Kaneez Fatima
MHMOHAMMAD HASANAIN
MOHAMMAD HASANAIN
CBChittaranjan Behera
Chittaranjan Behera
AKAvneet Kour
Avneet Kour
ANArvind S. Negi
Arvind S. Negi

1 September 2014 in Steroids
Verified
Journal Article
Closed access
AHA.A. Hamid
A.A. Hamid
MHMOHAMMAD HASANAIN
MOHAMMAD HASANAIN
Arjun SinghArjun Singh
Arjun Singh
BBBalakishan Bhukya
Balakishan Bhukya
OMOmprakash
Omprakash
ANArvind S. Negi
Arvind S. Negi